Home > Resources > Whitepapers > ACCELERATING

ACCELERATING

The Indian biotechnology industry is on the cusp of entering a new era when it can provide significant economic growth and development to the people of India and around the world. India already has many of the necessary ingredients needed in order to grow its bioeconomy, such as a talented and enthusiastic scientific workforce.

Spotlight

Syngene -Clinical Development

Syngene is a leading Asian CRO that provides a broad range of discovery, development, manufacturing and clinical development solutions to biopharma companies. Syngene's clinical development services span a broad spectrum of activities including human pharmacology, bioanalytical research, central laboratory, clinical operations, medical writing, medical monitoring, safety management, pharmacovigilance, clinical data management & biostatistics and regulatory services supporting early-phase through late-phase clinical development programs.

OTHER WHITEPAPERS

Accelerating Global Access to Gene Therapies: Case Studies from Lowand Middle-Income Countries

whitePaper | October 18, 2022

This document is published by the World Economic Forum as a contribution to a project, insight area or interaction. The findings, interpretations and conclusions expressed herein are a result

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

whitePaper | March 9, 2023

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

bFGF Supports Human ES Cell Self-Renewal

whitePaper | March 24, 2023

Basic fibroblast growth factor (bFGF) is an important cytokine used to support the growth and self renewal of human embryonic stem cells.

Advanced Treatments Gene and Cell Therapy

whitePaper | April 26, 2022

Public Policy Projects (PPP) is a global policy institute offering practical analysis and development across a range of sectors, including health and social care.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.

Gene and cell therapy analytical and development methods

whitePaper | April 20, 2023

In the three decades that have passed since the approval of the first gene therapy in 1990, these revolutionary medicines have changed the lives of patients all over the world1.